dyslipidemia along with hypertension, obesity, and cigarette smoking are established risk factors for premature heart disease. 1 The third report of the National cholesterol Education Program adult Treatment Panel (NcEP aTP iii) recommends a low-density lipoprotein cholesterol (ldl-c) goal of <2.6 mmol/l (<100 mg/dl) for patients with high risk for coronary artery disease (cad) or cad risk equivalent and <3.4 mmol/l (<130 mg/dl) for patients with moderate risk for cad. 2,3 although statins have been shown to be effective in lowering ldl-c and decreasing mortality, 4 40-80 % of individuals on statin monotherapy fail to achieve guideline-recommended ldl-c levels, with the lowest success rate for ldl-c goal achievement seen in patients with the highest risk for cad. Abstract dyslipidemia is an established risk factor for cardiovascular disease. While statin therapy remains the most important component of dyslipidemia management, a substantial proportion of patients on statin monotherapy fails to achieve guideline-recommended lipid levels. Ezetimibe is a secondline lipid-lowering agent that reduces sterol absorption, and has a favorable effect on lipid profile. This article reviews studies examining the role of ezetimibe on lipid profile, metabolic biomarkers, and cardiovascular outcomes in individuals with metabolic diseases. Special focus is given to studies in patients with dyslipidemia, Type 2 diabetes, and the metabolic syndrome. The controversy surrounding the role of ezetimibe in mitigating atherosclerosis is also highlighted. The article concludes that the ezetimibe-statin combination improves lipid parameters and helps attain guidelinerecommended lipid goals in patients with metabolic diseases. however, further research is needed to better understand the role of ezetimibe monotherapy, and the impact of ezetimibe on clinical cardiovascular outcomes.
What is Ezetimibe?
Ezetimibe is a lipid-lowering agent that prevents sterol absorption by selectively inhibiting the Niemann Pick c1 like 1 Protein (NPc1l1) at the jejunal brush border. shown to increase the hdl-c level, 22 and decrease triglyceride and apoB levels. [23] [24] [25] Ezetimibe also has a favorable metabolic profile with limited drug-drug interactions as it does not induce nor inhibit cytochrome P450 system. it is primarily metabolized by the liver and excreted in feces, and usually no severe side effects are noted with its use. despite these salutary effects and the approval for use by regulatory agencies based on its efficacy in improving lipid profile, 26 evidence from recent trials examining carotid intima-media thickness (ciMT) as a surrogate for atherosclerosis have raised questions about the added beneficial role of ezetimibe in the treatment of atherosclerotic vascular diseases. 27 
Ezetimibe and Cardiovascular Events
Two trials (see Table 1 ) have assessed the efficacy of ezetimibe and statin combination therapy in reducing major cardiovascular events. No trial has evaluated the impact of ezetimibe monotherapy on clinical outcomes.
intensive lipid lowering was seen in the Simvastatin and Ezetimibe in aortic Stenosis (SEaS) trial-a randomized double-blind trial involving 1,873 participants with mild-to-moderate asymptomatic aortic stenosis.
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The participants received either 10 mg of ezetimibe plus 40 mg simvastatin or placebo daily. after a median follow up of 52 months, the primary outcome of a composite of major cardiovascular events was not different in the two groups. trials that included more than 6,000 patients with diabetes and more than 1,500 patients without diabetes showed that while patients with diabetes and without diabetes both had a more favorable lipid outcomes with the ezetimibe-statin combination than with statin monotherapy, patients with diabetes achieved significantly larger reductions in ldl-c, total cholesterol and non-hdl-c compared with patients without diabetes. 36 an earlier study comparing ezetimibe-simvastatin to atorvastatin in patients with Type 2 diabetes showed that ezetimibe 10 mg plus simvastatin 20 mg reduced ldl-c 15.3 % more than atorvastatin 10 mg, and ezetimibe 10 mg plus simvastatin 40 mg reduced ldl-c 6.7 % more than atorvastatin 40 mg.
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Similarly, ezetimibe-statin combination therapy yielded significantly greater reductions in triglyceride and hs-cRP levels, and an increase in hdl-c level than atorvastatin monotherapy. The combination therapy also resulted in more patients achieving their ldl goals. however, treatment of patients with diabetes may be more complicated as diabetic dyslipidemia is often associated with lower ldl-c levels and higher levels of small-dense ldl (sd-ldl), triglyceride, and apoB levels, 38 which is now emerging as a potentially important cardiovascular risk mediator, [39] [40] [41] and ezetimibe has had inconsistent effects on sd-ldl levels. a recent small randomized study of six-week duration involving 40 patients with diabetes
showed that the sd-ldl level decreased by 20 %, 24 %, and 33 % with ezetimibe 10 mg, simvastatin 20 mg and the combination of ezetimibe 10 mg plus simvastatin 20 mg, respectively. 42 contrary to this observation, another small randomized study of 2-week duration involving 72 healthy men showed that ezetimibe monotherapy altered ldl subfraction distribution towards a more atherogenic profile by significantly increasing the sd-ldl level. 43 Further research is needed to better elucidate the clinical importance of ldl subfractions and it is currently unclear if ezetimibe induced sd-ldl particles behave differently from normal ldl particles. There was also a more favorable apolipoprotein profile and a significantly lower ldl-c and hs-cRP levels with ezetimibe-statin combination therapy across all subgroups.
There is emerging evidence suggesting ezetimibe's positive impact on a number of the metabolic syndrome-related parameters and biomarkers.
it has been postulated that ezetimibe may improve insulin resistance and increase serum adiponectin levels. 48, 49 Ezetimibe monotherapy has also been observed to be associated with an improvement in visceral fat area, fasting insulin level, homeostasis model assessment of insulin resistance and hs-cRP level in patients with fatty liver. 50 hs-cRP is an important inflammatory biomarker related to adverse cardiovascular outcomes, 51, 52 and studies have consistently shown a significant reduction in hs-cRP levels with ezetimibe-statin combination therapy. 22 Whether these improvement in surrogate endpoints result in clinical benefit needs further research.
Ezetimibe Safety and Tolerability
Ezetimibe is generally well tolerated. a large meta-analysis with 14,497
patients from 18 randomized trials showed that the overall safety profile of ezetimibe-statin combination is similar to that of statin monotherapy. 53 however, subsidiary analysis of the SEaS trial data did raise a concern about the risk for cancer with ezetimibe-statin combination therapy as the combination therapy group had a significantly higher incidence of cancers than the placebo group (11.1 versus 7.5 %). 29 This was an unexpected finding that had not been observed in other studies, 
Ezetimibe and Carotid Intima-media Thickness
Ezetimibe has been shown in animal studies to reduce vascular inflammation and atherosclerosis. 55 ciMT is a commonly used surrogate measure of atherosclerotic vascular disease in clinical studies. ciMT predicts coronary atherosclerosis, 56 and is independently associated with adverse cardiovascular outcomes. 57 The relative risk for cad increases two-to threefold with each 0.03 mm increase per year in ciMT. 58 Thus, studies evaluating the role of ezetimibe on ciMT deserve special mention (see Table 3 ).
The randomized double-blind Simvastatin with or without Ezetimibe in ldl-c and hdl-c levels were randomized to extended-release niacin (target dose 2,000 mg per day) or ezetimibe 10 mg per day. 28 The primary outcome was the between-group difference in the change from baseline in the mean ciMT after 14 months. The trial was terminated early after niacin treatment showed superior efficacy to ezetimibe in reducing mean ciMT. Surprisingly, in a post hoc analysis, a paradoxical increase in ciMT was seen in participants with greater ldl-c reduction in the ezetimibe group. The incidence of major cardiovascular events was also higher in the ezetimibe group (5 versus 1 %). an additional analysis of the study showed that the cumulative exposure to niacin was related to the regression of ciMT whereas cumulative exposure to ezetimibe was related to the progression of ciMT. 
Conclusion
There is strong and consistent evidence that ezetimibe-statin combination improves lipid parameters and helps attain guideline recommended lipid goals in patients with metabolic diseases. This is especially important in patients who are unable to tolerate high-dose statin therapy. however, there is a dearth of evidence on ezetimibe monotherapy, and ezetimibe's role in alleviating atherosclerosis remains controversial. 
